Sanarus, Leading US Breast Care Physicians Partner For Visica 2 Treatment System For Fibroadenomas

Armen Hareyan's picture
Advertisement

Sanarus Medical announced a partnership with leading breast care physicians from select centers across the country. These Centers, including breast care physicians from Connecticut to California, will work in partnership with Sanarus to increase the awareness and availability of an innovative, non-surgical treatment option for women with benign breast tumors, known as fibroadenomas. Sanarus will host a gathering of these new Centers prior to the American College of Surgeons (ACS) annual meeting in New Orleans.

In partnership with Sanarus, these centers will participate in regional and national efforts to increase patient and primary care physician awareness of the Visica 2 treatment as a minimally invasive, highly safe and effective treatment alternative to surgical excision. These Centers will participate in a patient registry to document the clinical outcomes and patient satisfaction rates following Visica 2 treatment.

Additionally, these Centers are dedicated to expanding private health insurance coverage of this important treatment option, making it more widely available to women across the country. Sanarus plans to include as many as 20 centers in this program before the end of 2007.

Advertisement

"I am very pleased to be a part of this important program that will offer more options to my patients. This technology makes cryoablation easier and faster than ever before and not only does that make sense for my practice, it makes the procedure very appealing to my patients," said Andrew Kenler, M.D., a surgeon from Connecticut and one of the newly created Visica 2 Reference Centers.

Visica 2 Treatment System

The original Visica Treatment System received FDA market clearance in 2002 and has been proven highly safe and effective with more than 1,500 fibroadenomas treated. The innovative Visica 2 System has been available at select sites since April of 2007. The Visica 2 Treatment System uses liquid nitrogen as the freezing agent, obviating the need for large, high pressure tanks of argon and helium used in the original Visica Treatment System. Because nitrogen operates at colder temperatures than argon, it allows for a more efficient, faster treatment. The procedure can be completed in the physician's office, with most treatment times under 15 minutes. Early experience has shown excellent physician and patient satisfaction with the new Visica 2 Treatment System.

Sanarus will be demonstrating this ground breaking system at the American College of Surgeons (ACS) meeting, October 7-11 in New Orleans.

Advertisement